Amarantus Bioscience Holdings Inc (AMBS)

[Solantey]

One of the catalysts for Thursday's sell off?

F.D.A. Acts on Lab Tests Developed In-House

"The decision, long in coming, has been fiercely opposed by some laboratories and pathologists, who have said that regulation by the agency is unnecessary and would significantly increase the cost and time needed to develop tests , stifling innovation and depriving patients of some vital tools.'

http://www.nytimes.com/2014/08/01/business/fd....html?_r=0


Check the 5 day chart on Quest Diagnostics. Appears to have had a definite impact:

http://finance.yahoo.com/q/bc?s=DGX+Basic+Chart&t=5d


Obviously it's a lot easier for a company such as Quest Diagnostics with a multitude of diagnostic test already in use to absorb the news than it is for a company such as AMBS with a single test in development.

Monday will be interesting.


p,s, I assume that Gerald is aware of this. Possibly he will address its potential impact in next week's blog.